Detalhe da pesquisa
1.
Randomized Trial of BCG Vaccine to Protect against Covid-19 in Health Care Workers.
N Engl J Med
; 388(17): 1582-1596, 2023 Apr 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37099341
2.
Borrowing information across patient subgroups in clinical trials, with application to a paediatric trial.
BMC Med Res Methodol
; 22(1): 49, 2022 02 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35184739
3.
ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
BMC Infect Dis
; 21(1): 5, 2021 Jan 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33446115
4.
Patterns of Drug Use and Drug-related Hospital Admissions in HIV-Positive and -Negative Gay and Bisexual Men.
AIDS Behav
; 20(10): 2372-2386, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26837635
5.
Impact of vaccine platform and BCG vaccination on antibody responses to COVID-19 vaccination.
Front Immunol
; 14: 1172851, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37465688
6.
Bacillus Calmette-Guérin vaccination for protection against recurrent herpes labialis: a nested randomised controlled trial.
EClinicalMedicine
; 64: 102203, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37719417
7.
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.
Lancet HIV
; 9(5): e341-e352, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35189082
8.
Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial.
Lancet HIV
; 7(8): e533-e544, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32763217
9.
Multi-arm, multi-stage randomised controlled trials for evaluating therapeutic HIV cure interventions.
Lancet HIV
; 6(5): e334-e340, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31047670
10.
Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial.
Antivir Ther
; 23(1): 21-32, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-28447585
11.
Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trial.
PLoS One
; 13(4): e0196239, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29684092
12.
Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
Lancet HIV
; 4(1): e13-e20, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27815068
13.
Poor record linkage sensitivity biased outcomes in a linked cohort analysis.
J Clin Epidemiol
; 75: 70-7, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-26836255
14.
Hospitalization for Anxiety and Mood Disorders in HIV-Infected and -Uninfected Gay and Bisexual Men.
J Acquir Immune Defic Syndr
; 73(5): 589-597, 2016 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27846072
15.
Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study.
AIDS Res Hum Retroviruses
; 32(9): 841-50, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27346600
16.
Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
Lancet HIV
; 2(2): e42-51, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26424460
17.
Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels.
AIDS
; 29(8): 911-9, 2015 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-25730509
18.
Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection.
PLoS One
; 10(2): e0118228, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25723472
19.
A new method for assessing how sensitivity and specificity of linkage studies affects estimation.
PLoS One
; 9(7): e103690, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25068293
20.
HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.
PLoS One
; 8(10): e77138, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24204757